PRNewsWire
23 Dec 2025, 16:10 UTC · 38w ago
Verdict
Headline leans bearish. We score RZLT −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Rezolute's Phase 3 sunRIZE clinical trial for its lead drug candidate, ersodetug, failed to meet both primary and key secondary endpoints.
So whatThe failure of a lead drug candidate in Phase 3 trials typically eliminates the primary catalyst for a biotech company's valuation.
More negative than 99% of claims this week
Rezolute (RZLT) shares plummeted approximately 85-90% on December 11, 2025, dropping from $10.94 to an intraday low near $0.90.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 98% of claims this week
Law firm Faruqi & Faruqi, LLP is investigating potential securities claims against Rezolute on behalf of investors who suffered losses.
More negative than 73% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
Shares plummeted 85-90% after Phase 3 clinical trial results failed to meet primary and secondary endpoints, leading to a securities investigation.
More negative than 79% of ticker scores this week
The company is mentioned as being under investigation for potential securities class action claims.
More negative than 79% of ticker scores this week
The company is mentioned as being under investigation for potential securities claims.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
+94.1%
Price is moving against the score
$3.98 vs $2.05 close before publication (Dec 22) · not market-adjusted
RZLT chart →
